PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
PharmNovo's CEO Per von Mentzer gave a presentation at the BioStock Investor Meeting on September 20 in Stockholm. Watch his presentation about the company's work in developing new treatments for neuropathic pain and how the phase I clinical study, which is in its final phase, is progressing. PharmNovo is now in the final phase of its clinical phase I study and is preparing a phase II study planned to start in 2024.
PharmNovo presented at the BioStock Investor Meeting
PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
PharmNovo's CEO Per von Mentzer gave a presentation at the BioStock Investor Meeting on September 20 in Stockholm. Watch his presentation about the company's work in developing new treatments for neuropathic pain and how the phase I clinical study, which is in its final phase, is progressing. PharmNovo is now in the final phase of its clinical phase I study and is preparing a phase II study planned to start in 2024.
Latest news
View all
Positive final Phase I results
The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.
Read more
Meet Bengt von Mentzer, founder and Chief scientific advisor
Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.
Read more
NIDA funds studies
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.
Read more
Meet Olof Breuer, MD, Clinical pharmacology lead
Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.
Read more